NCT04932915 (PREVENT) is a Phase 2 clinical trial of Niclosamide in Covid19, sponsored by UNION therapeutics.

Who is sponsoring NCT04932915?

NCT04932915 is sponsored by UNION therapeutics.

What drugs are being tested in NCT04932915?

Interventions in NCT04932915: Niclosamide, Placebo.

Is NCT04932915 still recruiting?

NCT04932915 is currently terminated. Last updated 21 February 2022.

Last reviewed 2022-02-21 · How we verify

NCT04932915: PREVENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

Terminated Phase 2 Last updated 21 February 2022

What this trial tests

Phase 2 trial testing Niclosamide in Covid19 in 4 participants. Terminated before completion.

Timeline

3 September 2021

Primary endpoint
10 January 2022

10 January 2022

Quick facts

Lead sponsor	UNION therapeutics
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	4
Start date	3 September 2021
Primary completion	10 January 2022
Estimated completion	10 January 2022
Sites	3 locations across Germany

Drugs / interventions tested

Niclosamide — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

UNION therapeutics — full company profile →

Who can join

Adults 45 to 80, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antibiotics in the clinical pipeline as of December 2022.
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. · · 2023 · cited 147× · PMID 37291465 · DOI 10.1038/s41429-023-00629-8
Niclosamide-A promising treatment for COVID-19.
Singh S, Weiss A, Goodman J, Fisk M, et al · · 2022 · cited 64× · PMID 35348204 · DOI 10.1111/bph.15843
Treatments for COVID-19: Lessons from 2020 and new therapeutic options.
Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, et al · · 2022 · cited 22× · PMID 34915400 · DOI 10.1016/j.coph.2021.11.002
Targeting SARS-CoV-2 and host cell receptor interactions.
Lim SP. · · 2023 · cited 15× · PMID 36581047 · DOI 10.1016/j.antiviral.2022.105514

Verify or expand the search:

Other trials of Niclosamide

Trials testing the same drug.

NCT04858425 — Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection · Phase 2 · terminated
NCT04870333 — PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V · Phase 2, PHASE3 · completed
NCT04705415 — A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers · Phase 1 · completed
NCT04644705 — Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat · Phase 1 · completed
NCT04603924 — Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients · Phase 2, PHASE3 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other UNION therapeutics trials

Trials by the same sponsor.

NCT05469464 — Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) · Phase 2 · completed
NCT05190419 — Study to Assess the Efficacy and Safety of Orismilast in Psoriasis · Phase 2 · completed
NCT04576312 — Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers · Phase 1 · completed
NCT04339985 — Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD · Phase 2 · completed
NCT03429595 — Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04932915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNION therapeutics
Last refreshed: 21 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing